Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection
Authors:
- 19 August 2003
- journal article
- clinical trial
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 139 (4) , 258-266
Abstract
Cannabinoid use could potentially alter HIV RNA levels by two mechanisms: immune modulation or cannabinoidprotease inhibitor interactions (because both share cytochrome P-450 metabolic pathways). To determine the short-term effects of smoked marijuana on the viral load in HIV-infected patients. Randomized, placebo-controlled, 21-day intervention trial. The inpatient General Clinical Research Center at the San Francisco General Hospital, San Francisco, California. 67 patients with HIV-1 infection. Participants were randomly assigned to a 3.95%-tetrahydrocannabinol marijuana cigarette, a 2.5-mg dronabinol (delta-9-tetrahydrocannabinol) capsule, or a placebo capsule three times daily before meals. HIV RNA levels, CD4+ and CD8+ cell subsets, and pharmacokinetic analyses of the protease inhibitors. 62 study participants were eligible for the primary end point (marijuana group, 20 patients; dronabinol group, 22 patients; and placebo group, 20 patients). Baseline HIV RNA level was less than 50 copies/mL for 36 participants (58%), and the median CD4+ cell count was 340 109 cells/L. When adjusted for baseline variables, the estimated average effect versus placebo on change in log10 viral load from baseline to day 21 was 0.07 (95% CI, 0.30 to 0.13) for marijuana and 0.04 (CI, 0.20 to 0.14) for dronabinol. The adjusted average changes in viral load in marijuana and dronabinol relative to placebo were 15% (CI, 50% to 34%) and 8% (CI, 37% to 37%), respectively. Neither CD4+ nor CD8+ cell counts appeared to be adversely affected by the cannabinoids. Smoked and oral cannabinoids did not seem to be unsafe in people with HIV infection with respect to HIV RNA levels, CD4+ and CD8+ cell counts, or protease inhibitor levels over a 21-day treatment.Keywords
This publication has 35 references indexed in Scilit:
- Interactions among Drugs for HIV and Opportunistic InfectionsNew England Journal of Medicine, 2001
- Pharmacodynamics of Human Immunodeficiency Virus Type 1 Protease InhibitorsClinical Infectious Diseases, 2000
- Medical Marijuana: Tribulations and TrialsJournal of Psychoactive Drugs, 1998
- Recent advances in the metabolism of cannabinoidsThe International Journal of Biochemistry & Cell Biology, 1995
- Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDSJournal of Pain and Symptom Management, 1995
- Involvement of CYP2C in the Metabolism of Cannabinoids by Human Hepatic Microsomes from an Old Woman.Biological and Pharmaceutical Bulletin, 1995
- Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDSThe American Journal of Clinical Nutrition, 1989
- A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapyCancer, 1981
- Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interactionClinical Pharmacology & Therapeutics, 1980
- Effects of delta‐9‐tetrahydrocannabinol on drug distribution and metabolism Antipyrine, pentobarbital, and ethanolClinical Pharmacology & Therapeutics, 1977